A study was conducted on the genotoxicity of @entity19644 ( @entity16905 ) in @entity19 oocytes. Superovulated female @entity19 were injected intraperitoneally with @entity16905 and mated with untreated males. Oocyte exposure occurred approximately 1.5 days before ovulation. @entity16905 doses ranged between 26 and 52 mg/kg. @entity2008 were scored in C-banded metaphases of one-cell embryos. The percentage of mated females, the average number of zygotes harvested per female, the frequencies of unfertilized oocytes and developmentally delayed zygotes did not reveal any overt sign of chemical @entity137 which hindered the propensity of animals to mate or affected the ovulation, fertilization, or cell cycle progression of treated oocytes. A dose-dependent induction of chromosome aberrations was observed which was best fitted by a linear-quadratic equation. Half of all the aberrations transmitted by @entity16905 -treated oocytes were chromatid-type breaks or exchanges. Among chromosome-type aberrations, double fragments for exceeded chromosome exchanges. This spectrum of structural aberrations differed markedly from what was previously observed in one-cell embryos conceived by @entity16905 -treated sperm, where 97% were chromosome-type aberrations and 40% were dicentrics or translocations. This difference suggests that chromosome damage in one-cell embryos can be fixed by different mutagenic pathways influenced by the targeted gamete and its specific chromatin configuration. After exposure to the same dose, oocytes transmitted to one-cell embryos between 4 and 8 times fewer aberrations than @entity16905 -treated sperm. While the rate of aberration induction suggests that female germ cells may be less at risk than mature sperm, especially at low-dose levels, the higher threshold for reproductive @entity137 observed in female than in male @entity19 may justify inclusion of data on female germ cell mutagenicity in the genetic risk assessment of @entity21430 exposure.

Induction and transmission of chromosome aberrations in @entity19 oocytes after treatment with XXXX .

@entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity16905 :: ('CHEBI:23704', 'Chemical') :: ['DEB'] @entity19644 :: ('MESH:C007366', 'Chemical') :: ['butadiene diepoxide'] @entity2008 :: ('MESH:D002869', 'Disease') :: ['Chromosome aberrations'] @entity21430 :: ('MESH:D002070', 'Chemical') :: ['butadiene']
@entity19644 :: (MESH:C007366,Chemical) :: ['butadiene diepoxide']
